0.753
price down icon1.16%   -0.0058
after-market アフターアワーズ: .78 0.027 +3.59%
loading
前日終値:
$0.7588
開ける:
$0.7936
24時間の取引高:
41,427
Relative Volume:
0.02
時価総額:
$3.18M
収益:
-
当期純損益:
$-120.30K
株価収益率:
-1.3688
EPS:
-0.5501
ネットキャッシュフロー:
$-7.29M
1週間 パフォーマンス:
-10.35%
1か月 パフォーマンス:
-16.98%
6か月 パフォーマンス:
-61.81%
1年 パフォーマンス:
-96.09%
1日の値動き範囲:
Value
$0.7409
$0.7936
1週間の範囲:
Value
$0.7154
$0.84
52週間の値動き範囲:
Value
$0.702
$25.26

Revelation Biosciences Inc Stock (REVB) Company Profile

Name
名前
Revelation Biosciences Inc
Name
セクター
Healthcare (1196)
Name
電話
650-800-3717
Name
住所
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Name
職員
9
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
REVB's Discussions on Twitter

REVB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
REVB 0.753 3.18M 0 -120.30K -7.29M -0.5501
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Revelation Biosciences Inc (REVB) 最新ニュース

pulisher
Nov 20, 2024

Warning: REVB is at high risk of performing badly - MSN

Nov 20, 2024
pulisher
Nov 12, 2024

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - BioSpace

Nov 12, 2024
pulisher
Nov 12, 2024

Revelation Bio Achieves Key Manufacturing Milestone for Kidney Disease Drug Trial | REVB Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com

Nov 11, 2024
pulisher
Nov 11, 2024

Allergic Rhinitis Treatment Market Size in the 7MM is expected to Grow by 2034 | DelveInsight - Barchart

Nov 11, 2024
pulisher
Nov 11, 2024

REVB: Good Expense Control as Company Prepares for Trials - Research Tree

Nov 11, 2024
pulisher
Nov 11, 2024

Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews

Nov 11, 2024
pulisher
Nov 11, 2024

Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

REVB Results Set Stage for Future Growth - Yahoo Finance

Nov 11, 2024
pulisher
Nov 08, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - sharewise

Nov 08, 2024
pulisher
Nov 08, 2024

Revelation Biosciences Inc expected to post a loss of $2.29 a shareEarnings Preview - XM

Nov 08, 2024
pulisher
Nov 08, 2024

Revelation Bio Q3 Loss Narrows to $2.2M, Secures $3.8M from Warrants Amid Cash Decline | REVB Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 08, 2024

Revelation Biosciences Inc (REVB) Quarterly 10-Q Report - Quartzy

Nov 08, 2024
pulisher
Oct 27, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN

Oct 27, 2024
pulisher
Oct 21, 2024

Revelation Biosciences faces Nasdaq delisting over noncompliance - Investing.com India

Oct 21, 2024
pulisher
Oct 03, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.43% - MSN

Oct 03, 2024
pulisher
Oct 02, 2024

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Oct 02, 2024
pulisher
Sep 25, 2024

A better buy-in window may exist right now for Revelation Biosciences Inc (REVB) - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

Revelation Biosciences Inc Inc. (REVB) Price Performance: A Guide to Technical Indicators - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Farallon Capital Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Revolution Medicines added to Analyst Focus List at JPMorgan - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 - Morningstar

Sep 24, 2024
pulisher
Sep 24, 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Revolution Medicines (NASDAQ:RVMD) Trading Down 6.1% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

A stock that deserves closer examination: Revelation Biosciences Inc (REVB) - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Revance Therapeutics Shares Fall on Crown Labs Deal Delay - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Financial Fitness Check: Examining Revelation Biosciences Inc (REVB)’s Key Ratios - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Revance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane dispute - Seeking Alpha

Sep 23, 2024
pulisher
Sep 21, 2024

Revolve Group (NYSE:RVLV) Reaches New 1-Year High at $25.96 - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Revelation Biosciences stock hits 52-week low at $0.78 - Investing.com India

Sep 21, 2024
pulisher
Sep 21, 2024

Revelation Biosciences stock hits 52-week low at $0.78 By Investing.com - Investing.com Australia

Sep 21, 2024
pulisher
Sep 18, 2024

Revolution Medicines executive sells over $500k in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines COO sells over $191k in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines CFO sells over $99k in company stock - Investing.com India

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines executive sells over $200k in company stock - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines general counsel sells shares worth over $64k By Investing.com - Investing.com UK

Sep 18, 2024
pulisher
Sep 17, 2024

Renovaro faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 17, 2024

The growth track for Revolution Medicines Inc (RVMD) has changed recently - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

Crown Labs tender offer for Revance delayed, expect deal to be completedanalyst - MSN

Sep 17, 2024
pulisher
Sep 17, 2024

Revelation Pharma Announces Revelation Wholesale, an Extension of Its National Compounding Network - PR Newswire

Sep 17, 2024
pulisher
Sep 17, 2024

455,099 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Sofinnova Investments Inc. - MarketBeat

Sep 17, 2024
pulisher
Sep 16, 2024

Revolve Group (NYSE:RVLV) Trading Down 5.2% - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update) - Seeking Alpha

Sep 16, 2024
pulisher
Sep 13, 2024

RVLV stock soars to 52-week high, touches $24.67 - Investing.com

Sep 13, 2024
pulisher
Sep 02, 2024

Financial Metrics Check: Revelation Biosciences Inc (REVB)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 02, 2024
pulisher
Aug 30, 2024

United States shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN

Aug 30, 2024
pulisher
Aug 26, 2024

Revelation Biosciences announces warrant exercise and inducement - Investing.com India

Aug 26, 2024
pulisher
Aug 25, 2024

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Manchestertimes

Aug 25, 2024
pulisher
Aug 23, 2024

Stock Performance Spotlight: Revelation Biosciences Inc (REVB) Ends the Day at 1.25, Down by -40.19 - The Dwinnex

Aug 23, 2024
pulisher
Aug 22, 2024

Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results - Benzinga

Aug 22, 2024
pulisher
Aug 22, 2024

Gold Down Over 1%; US Initial Jobless Claims Increase - Benzinga

Aug 22, 2024

Revelation Biosciences Inc (REVB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
大文字化:     |  ボリューム (24 時間):